Blood Advances · 2023 · 29 citations · 20 references
MedicineHematologyCell TherapyStem Cell TransplantationTransplant ImmunologyAllogeneic Stem Cell TransplantationCord Blood TransplantationDonor MatchingHematopoietic Stem Cell TransplantationTransplant OutcomesTransplant SurvivalAdult Cord Blood TransplantationMatched Unrelated Donor TransplantationPropensity Score AdjustmentRelapse-free SurvivalSurvival After Allogeneic TransplantationSurvival After Cord Blood TransplantationTransplantation Outcome AssessmentUnrelated Donation
Cord blood (CB) transplantation is hampered by low cell dose and high nonrelapse mortality (NRM). A phase 1-2 trial of UM171-expanded CB transplants demonstrated safety and favorable preliminary efficacy. The aim of the current analysis was to retrospectively compare results of the phase 1-2 trial with those after unmanipulated CB and matched-unrelated donor (MUD) transplants. Data from recipients of CB and MUD transplants were obtained from the Center for International Blood and Marrow Transplant Research (CIBMTR) database. Patients were directly matched for the number of previous allogeneic hematopoietic stem cell transplants (alloHCT), disease and refined Disease Risk Index. Patients were further matched by propensity score for age, comorbidity index, and performance status. Primary end points included NRM, progression-free survival (PFS), overall survival (OS), and graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) at 1 and 2 years after alloHCT. Overall, 137 patients from CIBMTR (67 CB, 70 MUD) and 22 with UM171-expanded CB were included. NRM at 1 and 2 years was lower, PFS and GRFS at 2 years and OS at 1 year were improved for UM171-expanded CBs compared with CB controls. Compared with MUD controls, UM171 recipients had lower 1- and 2-year NRM, higher 2-year PFS, and higher 1- and 2-year GRFS. Furthermore, UM171-expanded CB recipients experienced less grades 3-4 acute GVHD and chronic GVHD compared with MUD graft recipients. Compared with real-world evidence with CB and MUD alloHCT, this study suggests that UM171-expanded CB recipients may benefit from lower NRM and higher GRFS. This trial was registered at www.clinicaltrials.gov as #NCT02668315.
20
Madan Jagasia, Hildegard Greinix, Mukta Arora et al. · Biology of Blood and Marrow Transplantation · 2014 · 5.4K citations · Full text
1994 Consensus Conference on Acute GVHD Grading.
Donna Przepiorka, Daniel Weisdorf, Peyton Martin et al. · PubMed · 1995 · 5.1K citations
Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation
Philippe Armand, Haesook T. Kim, Brent R. Logan et al. · Blood · 2014 · 942 citations · Full text
Medicine, Hematology, Immunology +14
Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors
Claudio Anasetti, Brent R. Logan, Stephanie J. Lee et al. · New England Journal of Medicine · 2012 · 905 citations · Full text
Medicine, Hematology, Immunology +15
Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal
Iman Fares, Jalila Chagraoui, Yves Gareau et al. · Science · 2014 · 566 citations